top of page


Advanced Prenatal Therapeutics Featured in CEO/CFO Magazine

May 20, 2019

Advanced Prenatal Therapeutics was featured in the May 20, 2019 edition of CEO/CFO Magazine. In the issue, Dr. James Smith, President and CEO of APT, is interviewed by Lynn Fosse, Senior Editor, regarding APT’s mission, technology, progress, and Breakthrough Device Designation that was recently granted by the Food and Drug Administration.

APT VP of Business Development Attends US-China Trade Forum

May 10, 2019

Advanced Prenatal Therapeutics is pleased to announce that Daniel Thiel, Vice President of Business Development, participated as the Master of Ceremonies for the 2019 US-China Future Trade Forum held in Los Angeles, CA. In recognition of his support, Mr. Thiel received a Certificate of Congressional Recognition from US Congresswoman Judy Chu of the 27th district of California.

Advanced Prenatal Therapeutics Sponsors Preeclampsia Foundation

May 02, 2019

Advanced Prenatal Therapeutics is proud to announce that it has joined the Preeclampsia Foundation's Corporate Partner Program. The Preeclampsia Foundation is a non-profit organization with the mission to reduce maternal and infant illness and death due to preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy by providing patient support and education, raising public awareness, catalyzing research, and improving healthcare practices.


APT looks forward to supporting the Preeclampsia Foundation in its efforts to educate, support, and empower women with information and resources that improve their healthcare.

FDA Grants Breakthrough Device Designation For Advanced Prenatal Therapeutics’ Targeted Apheresis Column For Preeclampsia

April 17, 2019

Advanced Prenatal Therapeutics, Inc. (APT) announced today that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Device Designation for APT’s Targeted Apheresis Column for Preeclampsia (TAC-PE). The Designation enables APT to work collaboratively with the FDA to expedite development and regulatory timelines while maintaining a high level of compliance to standards for premarket approval.

APT Selected to Participate in MedTech Innovator Showcase

May 25, 2017

Los Angeles (May 25, 2017) – MedTech Innovator, the industry’s leading nonprofit global competition and accelerator, today announced the 50 early-stage companies selected to participate in the MedTech Innovator Showcase, an exhibition of the cutting-edge innovations to be presented at The MedTech Conference Sept. 25 to 27 in San Jose, Calif.

APT Receives Notice of Allowance for Preeclampsia Device

February 06, 2015

Advanced Prenatal Therapeutics, Inc., a private medical device company developing novel therapies for preeclampsia, is pleased to announce that its patent application for “Treatment of Preeclampsia Using Targeted Apheresis” has been allowed by the United States Patent and Trademark Office (USPTO). The patent describes technology that is the basis for its lead product, the Targeted Apheresis Column for Preeclampsia (TAC-PE), and is estimated to grant protection through at least 2030.

APT Appoints Dr. Nihar Nayak to Scientific Advisory Board

July 29, 2013

Advanced Prenatal Therapeutics, Inc. (APT), a private company developing the first medical device specifically designed to treat preeclampsia, is happy to announce the appointment of its first scientific advisor: Nihar Nayak, PhD, DVM. Dr. Nayak brings to the table over 16 years of research experience and a passion for the development of novel products to treat preeclampsia.

APT - Using Targeted Apheresis to Treat Preeclampsia

May 22, 2013

APT, a privately held company, is developing a medical device that will help alleviate the high blood pressure and other symptoms associated with preeclampsia. APT’s targeted apheresis cartridge is expected to be the first medical device specifically designed to treat preeclampsia, a leading cause of maternal and fetal death.

Please reload

bottom of page